Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690392 | 0.64 | CHRM2 (0.37) | — | |
| SCHEMBL2545095 | 0.61 | KDM4E (0.32) | MAPTKDM4ECYP3A4ALOX15LMNA | |
| SCHEMBL461672 | 0.60 | IDO1 (0.42) | MAPTLMNAHTTKMT2A | |
| SCHEMBL10784398 | 0.59 | IDO1 (0.49) | MAPTKDM4ELMNAKMT2A | |
| SCHEMBL6843663 | 0.59 | MEN1 (0.41) | MAPTKDM4ECYP3A4ALOX15ALDH1A1 | |
| SCHEMBL22470816 | 0.58 | KDM4E (0.32) | MAPTKDM4ECYP3A4ALOX15 | |
| SCHEMBL6326740 | 0.58 | NSD2 (0.37) | MAPTKDM4EALDH1A1LMNAPOLB | |
| SCHEMBL10627461 | 0.58 | CYP1A2 (0.44) | MAPTKDM4ECYP3A4ALOX15LMNA | |
| SCHEMBL1702617 | 0.57 | SLC6A2 (0.42) | — | |
| SCHEMBL8583801 | 0.57 | CYP2C19 (0.42) | MAPTKDM4ECYP3A4ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071339-B2 | Process for preparing functionalized γ-butyrolactones from mucohalic acid | WARNER LAMBERT COMPANY LLC (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1537095-B1 | PROCESS FOR PREPARING FUNCTIONALIZED GAMMA-BUTYROLACTONES FROM MUCOHALIC ACID | WARNER LAMBERT CO (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1537095-A1 | PROCESS FOR PREPARING FUNCTIONALIZED -BUTYROLACTIONES FROM MUCOHALIC ACID | Warner-Lambert Company LLC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040049058-A1 | Process for preparing functionalized gamma-butyrolactiones from mucohalic acid | BELMONT DANIEL (US) | 2004-03-11 | — | — | US | disclosed |
| WO-2004020424-A1 | PROCESS FOR PREPARING FUNCTIONALIZED -BUTYROLACTIONES FROM MUCOHALIC ACID | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049058-A1 | Process for preparing functionalized gamma-butyrolactiones from mucohalic acid | MUC1, ALG1, ST3GAL3 | MAPT 4800/4885KDM4E 2782/4885CYP3A4 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.